FDA 510(k) clearance for MEDIFLY maggots drives CUPR surge

 

FDA 510(k) clearance for MEDIFLY maggots drives 173% CUPR surge

• Cuprina announced U.S. FDA 510(k) clearance for MEDIFLY Maggots using Lucilia cuprina larvae, the first such U.S. approval.
• Product cleared for debriding non-healing necrotic skin and soft tissue wounds including diabetic foot and pressure ulcers.
• Clearance grants U.S. commercial rights to both Lucilia sericata and cuprina MDT species per GlobeNewswire release.
• CEO David Quek noted it anchors their wound-care platform in a key regulatory market with a competitive edge.
• Follows Nasdaq compliance news from June 12; stock gapped from $3.97 close to highs above $11 in premarket.
• High volume reflects momentum trading in this small-cap biomedical stock focused on chronic wound therapies.

https://finviz.com/stock?t=CUPR&p=d